Trinity Biotech Begins Brazil Launch of IFCC Gold Premier Hb9210 System
Trinity Biotech has commenced commercial rollout in Brazil of its next-generation Premier Hb9210™ HbA1c column system after receiving local regulatory approval. The platform is the only HbA1c system granted IFCC Gold classification for 2026, targeting one of the world’s largest diabetes markets with 16–18 million adult patients.
1. Product Rollout in Brazil
Trinity Biotech has begun the commercial rollout of its upgraded Premier Hb9210™ HbA1c column system in Brazil following local regulatory approval, marking the system’s first entry into one of the world’s top diabetes markets.
2. IFCC Gold Classification
The Premier Hb9210™ platform is the sole HbA1c system worldwide awarded IFCC Gold classification for 2026, reflecting the highest standards in accuracy, precision and traceability for clinical diagnostics.
3. Brazil Market Opportunity
Brazil has an estimated 16–18 million adults living with diabetes and rising prevalence across urban and rural areas, creating strong demand for high-specificity HbA1c testing technologies.
4. Strengthened Commercial Leadership
Trinity Biotech appointed Bruna Gigliotti to lead its Brazilian commercial organisation, aiming to accelerate product adoption and reinforce market execution for the Premier Hb9210™ platform.